Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;16(4):5455-5462.
doi: 10.3892/ol.2018.9236. Epub 2018 Jul 31.

Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma

Yasuhiro Arakawa  1 , Yoshihiro Shirai  2 , Kazumi Hayashi  1 , Yujiro Tanaka  2 , Akira Matsumoto  2 , Katsunori Nishikawa  2 , Shingo Yano  1
Affiliations

Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma

Yasuhiro Arakawa et al. Oncol Lett. 2018 Oct.

Abstract

Combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (DCF) is a promising treatment option for patients with advanced esophageal squamous cell carcinoma (ESCC), although its clinical application is limited by severe systemic toxicities. There are no validated markers for predicting the adverse effects caused by this regimen. This pharmacogenetic study enrolled 57 patients with chemotherapy-naive advanced ESCC between July 2012 and March 2016 (UMIN000008462). All patients received at least one course of DCF chemotherapy (docetaxel, 60 mg/m2 on day 1; cisplatin, 70 mg/m2 on day 1; 5-fluorouracil, 600 mg/m2 on days 1-5). The associations between four gene polymorphisms (ERCC1 rs11615, GSTP1 rs1695, TYMS rs151264360 and XPD rs13181) and the development of grade 3/4 adverse events during the first course of chemotherapy were prospectively investigated. The patients had a median age of 66 years (range, 45-77 years) and the majority were male (51 males vs. 6 females). The treatment settings were neoadjuvant (47 patients), adjuvant (1 patient) and salvage (9 patients), with dose intensities of 100% (51 patients) or 80% (6 patients). The severe adverse events were leukopenia (70.2%), neutropenia (86.0%), febrile neutropenia (36.8%), acute kidney injury (29.1%) and hyponatremia (43.9%). Two polymorphisms were independently associated with the development of severe hyponatremia among patients carrying the minor allele (vs. patients with major homozygote genotype): TYMS 3'-UTR rs151264360 (odds ratio, 3.64; 95% confidence interval, 1.11-11.9) and XPD Lys751Gln rs13181 (odds ratio, 10.1; 95% confidence interval, 1.10-93.3). Therefore, the presence of the TYMS and XPD polymorphisms may aid in identifying patients with a high risk of developing severe hyponatremia during DCF chemotherapy.

Keywords: chemotherapy; esophageal cancer; pharmacogenetic study; severe toxicity; squamous cell carcinoma.

PubMed Disclaimer

References

    1. Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Yatabe Y, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31:3535–3541. - PubMed
    1. Tamura S, Imano M, Takiuchi H, Kobayashi K, Imamoto H, Miki H, Goto Y, Aoki T, Peng YF, Tsujinaka T, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403) Anticancer Res. 2012;32:1403–1408. - PubMed
    1. Sugawara M, Katada C, Katada N, Takahashi K, Higuchi K, Komori S, Moriya H, Ishiyama H, Yamashita K, Sakuramoto S, et al. Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma. Esophagus. 2013;10:65–69. doi: 10.1007/s10388-013-0365-9. - DOI
    1. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ. A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91:344–354. doi: 10.1038/sj.bjc.6601975. - DOI - PMC - PubMed
    1. Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, Cortés A, Barnadas A, Baiget M. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer. 2008;99:1050–1055. doi: 10.1038/sj.bjc.6604671. - DOI - PMC - PubMed